J Lipid Atheroscler.
2022 Jan;11(1):1-19. 10.12997/jla.2022.11.1.1.
SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
- Affiliations
-
- 1Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- 2Cardiology Division, Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- KMID: 2525232
- DOI: http://doi.org/10.12997/jla.2022.11.1.1
Abstract
- Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as powerful drugs that can be used to treat heart failure (HF) patients, both with preserved and reduced ejection fraction and in the presence or absence of type 2 diabetes. While the mechanisms underlying the salutary effects of SGLT2 inhibitors have not been fully elucidated, there is clear evidence for a beneficial metabolic effect of these drugs. In this review, we discuss the effects of SGLT2 inhibitors on cardiac energy provision secondary to ketone bodies, pathological ventricular remodeling, and inflammation in patients with HF. While the specific contribution of ketone bodies to the pleiotropic cardiovascular benefits of SGLT2 inhibitors requires further clarification, ketone bodies themselves may also be used as a therapy for HF.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- SGLT2 Inhibitors and Diabetes: Where Does It Come from and Where Does It Go?
- SGLT2 Inhibitors: Emerging Drugs in Heart Failure
- Prevention of Major Adverse Cardiovascular and Renal Outcomes with Sodium-Glucose Cotransporter 2 Inhibitors
- The Potential Cardioprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors
- Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art Review and Future Potentials
